CSF2 and non-Hodgkin lymphoma: Also, a pilot study of three patients, one with refractory Non-Hodgkin lymphoma (NHL) and two with multiple myelomas (MMs) with CART-aIL6/IL1RA with GM-CSF/TCR KO showed 3/3 complete response, 2/3 with no CRS incidence, one with grade 2 CRS incidence and no neurotoxicity which proved safety and efficacy of CART-aIL6/IL1RA with GM-CSF/TCR KO.